div class="xn-content">
ALBUQUERQUE, N.M., July 8 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP).
The CAP is a leading organization of board-certified pathologists that serves patients, pathologists and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine. The CAP accreditation program, begun in the early 1960s, is recognized by the federal government as being equal to or more stringent than the government’s own inspection program. Exagen is one of more than 17,000 CAP-accredited laboratories in the world.
“We are extremely pleased to receive recognition for the high quality diagnostic services our laboratory provides,” said Exagen Clinical Laboratory Director John Hozier Ph.D., FACMG. “As we continue to develop new genomic tests independently and through partnerships with pharmaceutical and diagnostics companies, having CAP accreditation validates our position as one of the world’s most forward looking laboratories.”
The CAP awards accreditation based on the results of onsite inspections. During the process, inspectors examine the laboratory’s records and quality control procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, laboratory equipment, facilities, the laboratory’s safety program and record, in addition to overall management of the laboratory. This stringent inspection program is specifically designed to ensure the highest standard of care for all laboratory patients.
About the College of American Pathologists
The College of American Pathologists (CAP) is a medical society that serves more than 17,000 physician members and the laboratory community throughout the world. It is the world’s largest association composed exclusively of board certified pathologists and is widely considered the leader in laboratory quality assurance. The CAP is an advocate for high-quality and cost-effective patient care. More information about the CAP can be found at www.cap.org.
About Exagen Diagnostics
Exagen is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company’s proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna’s targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified using traditional analytical methods. For more information, please visit www.exagen.com.
SOURCE Exagen Diagnostics, Inc.
